AEGiS-Reuters: Measles research could hold hope for AIDS - report

Reuters, Ltd.Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
Click here to return to Reuters main menu


DonateNow


Measles research could hold hope for AIDS - report

Reuters NewMedia, Inc. - 11 July 1996


WASHINGTON (Reuter) - New research on measles, which kills as many as two million children each year, could help shed light on the opportunistic infections that attack AIDS patients, scientists reported Thursday.

One of the ways measles kills is by attacking the immune systems of the children who contract it, leaving them vulnerable to other diseases, according to Christopher Karp, one of the authors of the report in the journal Science.

Karp's research with other scientists focused on exactly how measles undermines immunity, and found that what happens in measles might also happen in the case of HIV, the virus that causes AIDS.

"It's preliminary, it's pure speculation, but it's exciting enough that we've put significant resources into finding out if it's a reasonable hypothesis," Karp said by telephone from Johns Hopkins University School of Medicine in Baltimore.

The possible AIDS link was a bonus discovery to the scientists' research, which focused on cutting measles' lethal impact among children in tropical regions.

Although a measles vaccine is available, it is more effective among children in rich, temperate countries than among those in tropical countries, which are often poorer, Karp said. This may occur because the natural immunity babies get from their mothers appears to decline faster in the tropics.

The researchers were working to develop a vaccine that would be more effective for these children, one that could be administered very early, possibly at the age of six months.

In the process, they found a way to shut off the flow of the substance that erodes immunity in measles sufferers.

What remains to be seen is whether the same method can be used to shut off the immunity-destroying properties in HIV, Karp said.
960711
RE960776


Copyright © 1996 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.   Contact Reuters.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .